NeuroPace at attractive entry point, remains best idea, says Cantor Fitzgerald

Cantor Fitzgerald tells investors in a research note that NeuroPace (NPCE) remains the firm’s best idea for 2025 and represents an attractive entry point with shares down 23% from their year-to-date high of $14.69. NeuroPace is set up well to exceed expectations as the company drives further adoption and utilization in existing Level 4 comprehensive epilepsy centers, and PROJECT CARE, a program designed to expand access to the RNS System outside of Level 4 comprehensive epilepsy centers, should lead to incremental growth as new centers serve as a referral point to CECs in addition to being a new site for implants, the firm says. Cantor has an Overweight rating and $20 price target on the shares.